Keytruda (pembrolizumab)

pCPA File Number: 20821
Negotiation Status:
Concluded with an LOI
Indication(s):
Metastatic Melanoma
Sponsor/Manufacturer:
Merck Canada Inc.
CDA-AMC Project Number:
PC0058-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: